21.9 C
New York
Thursday, July 3, 2025

Tag: checkpoint

Announcing New TSA PreCheck® “Serve with Honor, Travel with Ease” Benefits for the Military and Uniformed Service Community

Free for Gold Star families, discounted for military spouses and expedited lanes for service members WASHINGTON, July 2, 2025 /PRNewswire/ -- In recognition of Independence...

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H)...

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Oncology Innovation Just Hit a Turning Point — Here’s What to Watch

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...

Finding Suggests Treatment Approach for Autoimmune Diseases

NEW YORK, June 30, 2025 /PRNewswire/ -- An engineered protein turns off the kind of immune cells most likely to damage tissue as part...

Oncology Innovation Just Hit a Turning Point — Here’s What to Watch

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Global Cancer Immunotherapy Market Projected to Reach $247 Billion by 2029, Driven by 11.4% CAGR

"Harnessing the Power of the Immune System: How Cancer Immunotherapy and Oncolytic Virology Are Reshaping the Future of Oncology in a Digitally Driven Era" BOSTON,...

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s HMBD-002 for further clinical development

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCheckpoint